在全球生物市场利用特有技术积极开展事业
细胞批量培养技术 + 质量管理技术
兼具两种核心技术的企业
获得主导新药开发市场的
主要国家的专利
利用专利技术开拓国际市场
知识产权
我们通过建立知识产权保护核心技术
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 用于检测细胞硫醇水平的 实时成像传感器 |
韩国 | 10-1862581 | 2018. 05. 24 |
| 美国 | 10.215.757B2 | 2019. 02. 26 | |
| 韩国 | 10-1983803 | 2019. 05. 23 | |
| 美国 | 10.620.215 | 2020. 04. 14 | |
| 细胞器内谷胱甘肽检测用 实时荧光成像传感器及其制造方法 |
韩国 | 10-2133794 | 2020. 07. 08 |
| 加拿大（申请） | 3.072.434 | 2020. 02. 07 | |
| 澳大利亚（申请） | 2018320601 | 2020. 02. 19 | |
| 美国（申请） | 16/640717 | 2020. 02. 20 | |
| 欧洲（申请） | 18848372.1 | 2020. 02. 21 | |
| 中国（申请） | 201880054675.0 | 2020. 02. 21 | |
| 印度（申请） | 202017007994 | 2020. 02. 25 | |
| 日本（申请） | 2020-511502 | 2020. 02. 19 | |
| 内质网内谷胱甘肽检测用 实时荧光成像传感器及其使用方法 |
韩国 | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 基于 FreSHtracer 分离的细胞 基因配置文件的应用 |
PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 用于治疗血小板减少症的组合物 | 韩国 | 10-2021-0063975 | 2021. 05. 18 |
| 用于评估干细胞特性的 基因标记及其用途 |
韩国 | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 通过实时检测谷胱甘肽， 提高治疗用细胞质量的方法 |
韩国 | 10-2119714 | 2020. 06. 01 |
| 欧洲（申请） | 18883520.1 | 2020. 05. 27 | |
| 中国（申请） | 201880077266.2 | 2020. 05. 28 | |
| 日本（申请） | 2020-546264 | 2020. 05. 27 | |
| 美国（申请） | 16/767985 | 2020. 05. 28 | |
| 通过实时检测谷胱甘肽， 检测治疗用细胞质量的方法 |
韩国 | 10-2145929 | 2020. 08. 12 |
| 美国（申请） | 16/768014 | 2020. 05. 28 | |
| 欧洲（申请） | 18884812.1 | 2020. 05. 27 | |
| 中国（申请） | 201880077236.1 | 2020. 05. 28 | |
| 日本（申请） | 2020-546265 | 2020. 05. 27 |
发表
接连在知名学术期刊上发表了研究成果
Development Technology and astrocytes : J. Song et al., Cografting astrocytes improves cell therapeutic outcomes in a Parkinson’s disease model, JCI, 2018, 128(1), 463-482
Transplantation of neural progenitor cells (NPCs) is a potential therapy for treating neurodegenerative disorders, but this
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.